Skip to main content
Loading

Diakonos Oncology

October 17, 2023
Franciscan C
Oncology
Diakonos Oncology is a clinical-stage biotechnology company, developing a novel "Double-Loaded" Dendritic Cell Vaccine (DCV) for the treatment of Glioblastoma Multiforme (GBM) as well as other difficult to treat cancer indications. Leveraging a patented multi-step process, Diakonos' DCV protocol initiates powerful and unique TH1 immunity against the patient's tumor. With statistically significant efficacy already achieved in unmethylated GBM, Diakonos Oncology's approach is poised to transform the landscape of cancer treatment. In addition, Diakonos' DCV protocol has had no observed off-target effects to date.
Speakers
Jay Hartenbach - Diakonos Oncology

Company Type

Privately Funded

Website

http://www.diakonosoncology.com

CEO/Top Company Official

Mike Wicks (m.wicks@diakonosoncology.com)

Lead Product in Development

"Double-Loaded" Dendritic Cell Vaccine for Glioblastoma Multiforme (GBM)

Number Of Unlicensed Products

2

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS